Reshape Lifesciences Inc. ( (HIND) ) has released its Q3 earnings. Here is a breakdown of the information Reshape Lifesciences Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Reshape Lifesciences Inc., now known as Vyome Holdings Inc., is a clinical-stage specialty pharmaceutical company focused on developing treatments for immune-inflammatory and rare diseases, with a notable presence in the US-Indian innovation corridor. The company recently completed a merger with Vyome Therapeutics, transitioning its focus to Vyome’s business and becoming a Nasdaq-listed entity under the ticker symbol ‘HIND’.
In its latest earnings report, Vyome Holdings Inc. highlighted significant changes following its merger with Vyome Therapeutics. The company reported a substantial increase in total assets, rising from $1.38 million at the end of 2024 to $7.05 million as of September 30, 2025. However, the company also recorded a significant net loss of $9.20 million for the nine months ended September 30, 2025, compared to a loss of $1.14 million during the same period in 2024.
Key financial metrics from the report include a notable increase in cash and cash equivalents, which rose to $5.71 million from $101,904 at the end of 2024. Despite the increase in revenue to $283,163 from $195,516 in the previous year, the company’s operating expenses surged to $9.29 million, primarily due to substantial transactional and financing advisory fees. The company also experienced a significant operating loss of $9.10 million.
Looking ahead, Vyome Holdings Inc. remains focused on advancing its lead program, VT-1953, and other assets in its pipeline. The company plans to engage with the FDA on pivotal trial protocols in early 2026. Management is optimistic about its financial position post-merger, with sufficient funds to support operations for the next 12 months, while continuing to seek additional financing to support its drug development initiatives.